The increase in plasma FGF21 in response to metabolic impairment and NAFLD may represent an adaptive protective response where increases in FGF21 may act to increase insulin sensitivity and decrease liver fat. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.